作者
Anahita Fathi Kazerooni,Adam Kraya,Komal S. Rathi,Meen Chul Kim,Varun Kesherwani,Ryan J. Corbett,Arastoo Vossough,Nastaran Khalili,Deep Gandhi,Neda Khalili,Ariana Familiar,Run Jin,Xiaoyan Huang,Yuankun Zhu,Alex Sickler,Matthew R. Lueder,Saksham Phul,Phillip B. Storm,Jeffrey B. Ware,Jessica Foster,Sabine Mueller,Jo Lynne Rokita,Michael J. Fisher,Adam Resnick,Ali Nabavizadeh
摘要
ABSTRACT Background Cancers show heterogeneity at various levels, from genome to radiological imaging. This study aimed to explore the interplay between genomic, transcriptomic, and radiophenotypic data in pediatric low-grade glioma (pLGG), the most common group of brain tumors in children. Methods We analyzed data from 201 pLGG patients in the Children’s Brain Tumor Network (CBTN), using principal component analysis and K-Means clustering on 881 radiomic features, along with clinical variables (age, sex, tumor location), to identify imaging clusters and examine their association with 2021 WHO pLGG classifications. To determine the transcriptome pathways linked to imaging clusters, we employed a supervised machine learning model with elastic net logistic regression based on the pathways identified through gene set enrichment and gene co-expression network analyses. Results Three imaging clusters with distinct radiomic characteristics were identified. BRAF V600E mutations were primarily found in imaging cluster 3, while KIAA1549::BRAF fusion occurred in subtype 1. The model’s predictive accuracy (AUC) was 0.77 for subtype 1, 0.78 for subtype 2, and 0.70 for subtype 3. Each imaging cluster exhibited unique molecular mechanisms: subtype 1 was linked to oxidative phosphorylation, PDGFRB , and interleukin signaling, whereas subtype 3 was associated with histone acetylation and DNA methylation pathways, related to BRAF V600E pLGGs. Conclusions Our radiogenomics study indicates that the intrinsic molecular characteristics of tumors correlate with distinct imaging subgroups in pLGG, paving the way for future multi-modal investigations that may enhance understanding of disease progression and targetability.